About: Pyrilutamide

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of androgenic alopecia (androgen-dependent scalp hair loss) and acne in China and the United States. As of October 2022, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne.

Property	Value
dbo:abstract	Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of androgenic alopecia (androgen-dependent scalp hair loss) and acne in China and the United States. As of October 2022, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne. (en)
dbo:class	dbr:Nonsteroidal_antiandrogen
dbo:thumbnail	wiki-commons:Special:FilePath/Pyrilutamide_high_res.png?width=300
dbo:wikiPageID	69472087 (xsd:integer)
dbo:wikiPageLength	5216 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1124095722 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Bicalutamide dbr:Androgen_receptor dbc:Imidazolidines dbc:Experimental_drugs dbc:Fluoroarenes dbc:Trifluoromethyl_compounds dbr:Contact_dermatitis dbr:Clinical_trial dbr:Receptor_antagonist dbc:Hair_loss_medications dbc:Nonsteroidal_antiandrogens dbc:Peripherally_selective_drugs dbc:Nitriles dbc:Oxazoles dbr:Androgenic_alopecia dbc:Dermatologic_drugs dbr:Acne dbr:Affinity_(pharmacology) dbr:Binding_selectivity dbr:IC50 dbr:Phases_of_clinical_research dbr:Topical_medication dbr:Nonsteroidal_antiandrogen dbr:Vellus_hair dbr:Silent_antagonist dbr:File:Kx.png
dbp:atcPrefix	None (en)
dbp:c	21 (xsd:integer)
dbp:class	dbr:Nonsteroidal_antiandrogen
dbp:f	5 (xsd:integer)
dbp:h	15 (xsd:integer)
dbp:iupacName	4 (xsd:integer)
dbp:n	4 (xsd:integer)
dbp:o	2 (xsd:integer)
dbp:routesOfAdministration	dbr:Topical_medication
dbp:s	1 (xsd:integer)
dbp:smiles	CNCC1=CC=CN1CNC1=CCCF (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	CGRMNGGGSWLDDC-UHFFFAOYSA-N (en)
dbp:synonyms	KX-826 (en)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Androgen_receptor_modulators dbt:Antineoplastic-drug-stub dbt:Citation_needed dbt:Clear dbt:Drugbox dbt:Reflist dbt:Short_description
dcterms:subject	dbc:Imidazolidines dbc:Experimental_drugs dbc:Fluoroarenes dbc:Trifluoromethyl_compounds dbc:Hair_loss_medications dbc:Nonsteroidal_antiandrogens dbc:Peripherally_selective_drugs dbc:Nitriles dbc:Oxazoles dbc:Dermatologic_drugs
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of androgenic alopecia (androgen-dependent scalp hair loss) and acne in China and the United States. As of October 2022, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne. (en)
rdfs:label	Pyrilutamide (en)
owl:sameAs	wikidata:Pyrilutamide https://global.dbpedia.org/id/GJgCV
prov:wasDerivedFrom	wikipedia-en:Pyrilutamide?oldid=1124095722&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Kx.png wiki-commons:Special:FilePath/Pyrilutamide_high_res.png
foaf:isPrimaryTopicOf	wikipedia-en:Pyrilutamide
is dbo:wikiPageWikiLink of	dbr:List_of_investigational_sex-hormonal_agents dbr:Topilutamide
is foaf:primaryTopic of	wikipedia-en:Pyrilutamide